Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 193

Similar articles for PubMed (Select 23406679)

1.

Epigenetic inactivation of the MIR129-2 in hematological malignancies.

Wong KY, Yim RL, Kwong YL, Leung CY, Hui PK, Cheung F, Liang R, Jin DY, Chim CS.

J Hematol Oncol. 2013 Feb 14;6:16. doi: 10.1186/1756-8722-6-16.

2.

Epigenetic inactivation of the miR-124-1 in haematological malignancies.

Wong KY, So CC, Loong F, Chung LP, Lam WW, Liang R, Li GK, Jin DY, Chim CS.

PLoS One. 2011 Apr 22;6(4):e19027. doi: 10.1371/journal.pone.0019027.

3.

Epigenetic inactivation of the hsa-miR-203 in haematological malignancies.

Chim CS, Wong KY, Leung CY, Chung LP, Hui PK, Chan SY, Yu L.

J Cell Mol Med. 2011 Dec;15(12):2760-7. doi: 10.1111/j.1582-4934.2011.01274.x.

4.

Epigenetic inactivation of the miR-34a in hematological malignancies.

Chim CS, Wong KY, Qi Y, Loong F, Lam WL, Wong LG, Jin DY, Costello JF, Liang R.

Carcinogenesis. 2010 Apr;31(4):745-50. doi: 10.1093/carcin/bgq033. Epub 2010 Jan 29. Erratum in: Carcinogenesis. 2014 Nov;35(11):2631.

5.

Epigenetic inactivation of miR-9 family microRNAs in chronic lymphocytic leukemia--implications on constitutive activation of NFκB pathway.

Wang LQ, Kwong YL, Kho CS, Wong KF, Wong KY, Ferracin M, Calin GA, Chim CS.

Mol Cancer. 2013 Dec 27;12:173. doi: 10.1186/1476-4598-12-173.

6.

Epigenetic silencing of MIR203 in multiple myeloma.

Wong KY, Liang R, So CC, Jin DY, Costello JF, Chim CS.

Br J Haematol. 2011 Sep;154(5):569-78. doi: 10.1111/j.1365-2141.2011.08782.x. Epub 2011 Jun 28.

PMID:
21707582
7.

Epigenetic inactivation of mir-34b/c in addition to mir-34a and DAPK1 in chronic lymphocytic leukemia.

Wang LQ, Kwong YL, Wong KF, Kho CS, Jin DY, Tse E, Rosèn A, Chim CS.

J Transl Med. 2014 Feb 22;12:52. doi: 10.1186/1479-5876-12-52.

8.

The promoter of miR-663 is hypermethylated in Chinese pediatric acute myeloid leukemia (AML).

Yan-Fang T, Jian N, Jun L, Na W, Pei-Fang X, Wen-Li Z, Dong W, Li P, Jian W, Xing F, Jian P.

BMC Med Genet. 2013 Jul 19;14:74. doi: 10.1186/1471-2350-14-74.

9.
10.

Discovery of novel epigenetic markers in non-Hodgkin's lymphoma.

Shi H, Guo J, Duff DJ, Rahmatpanah F, Chitima-Matsiga R, Al-Kuhlani M, Taylor KH, Sjahputera O, Andreski M, Wooldridge JE, Caldwell CW.

Carcinogenesis. 2007 Jan;28(1):60-70. Epub 2006 Jun 14.

11.

Metallothionein III (MT3) is a putative tumor suppressor gene that is frequently inactivated in pediatric acute myeloid leukemia by promoter hypermethylation.

Tao YF, Xu LX, Lu J, Cao L, Li ZH, Hu SY, Wang NN, Du XJ, Sun LC, Zhao WL, Xiao PF, Fang F, Li YH, Li G, Zhao H, Li YP, Xu YY, Ni J, Wang J, Feng X, Pan J.

J Transl Med. 2014 Jun 25;12:182. doi: 10.1186/1479-5876-12-182.

12.

Hypermethylation of the alternative AWT1 promoter in hematological malignancies is a highly specific marker for acute myeloid leukemias despite high expression levels.

Guillaumet-Adkins A, Richter J, Odero MD, Sandoval J, Agirre X, Catala A, Esteller M, Prósper F, Calasanz MJ, Buño I, Kwon M, Court F, Siebert R, Monk D.

J Hematol Oncol. 2014 Jan 9;7:4. doi: 10.1186/1756-8722-7-4.

13.

Epigenetic inactivation of the MIR34B/C in multiple myeloma.

Wong KY, Yim RL, So CC, Jin DY, Liang R, Chim CS.

Blood. 2011 Nov 24;118(22):5901-4. doi: 10.1182/blood-2011-06-361022. Epub 2011 Oct 5.

15.

Epigenetic silencing of the 3p22 tumor suppressor DLEC1 by promoter CpG methylation in non-Hodgkin and Hodgkin lymphomas.

Wang Z, Li L, Su X, Gao Z, Srivastava G, Murray PG, Ambinder R, Tao Q.

J Transl Med. 2012 Oct 11;10:209. doi: 10.1186/1479-5876-10-209.

16.

Epigenetic inactivation of INK4/CDK/RB cell cycle pathway in acute leukemias.

Chim CS, Wong AS, Kwong YL.

Ann Hematol. 2003 Dec;82(12):738-42. Epub 2003 Sep 25.

PMID:
14513284
17.

Expression of p16INK4A and p14ARF in hematological malignancies.

Taniguchi T, Chikatsu N, Takahashi S, Fujita A, Uchimaru K, Asano S, Fujita T, Motokura T.

Leukemia. 1999 Nov;13(11):1760-9.

PMID:
10557050
18.

Methylation of tumor suppressor microRNAs: lessons from lymphoid malignancies.

Wang LQ, Liang R, Chim CS.

Expert Rev Mol Diagn. 2012 Sep;12(7):755-65. doi: 10.1586/erm.12.64. Review.

PMID:
23153241
19.

Frequent epigenetic inactivation of the RASSF1A tumor suppressor gene in Hodgkin's lymphoma.

Murray PG, Qiu GH, Fu L, Waites ER, Srivastava G, Heys D, Agathanggelou A, Latif F, Grundy RG, Mann JR, Starczynski J, Crocker J, Parkes SE, Ambinder RF, Young LS, Tao Q.

Oncogene. 2004 Feb 12;23(6):1326-31.

PMID:
14961078
20.

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Plosker GL, Figgitt DP.

Drugs. 2003;63(8):803-43. Review.

PMID:
12662126
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk